These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 25963594)

  • 21. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients.
    Liabeuf S; Lenglet A; Desjardins L; Neirynck N; Glorieux G; Lemke HD; Vanholder R; Diouf M; Choukroun G; Massy ZA;
    Kidney Int; 2012 Dec; 82(12):1297-303. PubMed ID: 22895515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Magnesium and calciprotein particles in vascular calcification: the good cop and the bad cop.
    Zeper LW; de Baaij JHF
    Curr Opin Nephrol Hypertens; 2019 Jul; 28(4):368-374. PubMed ID: 31045659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy for the altered mineral metabolism of chronic kidney disease: implications for vascular calcification.
    Saab G; Whaley-Connell AT; Khanna R; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Dec; 1(2):107-12. PubMed ID: 19124399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anemia in chronic kidney disease and its cardiovascular implications].
    Cases A; Coll E; Collado S
    Med Clin (Barc); 2009 May; 132 Suppl 1():38-42. PubMed ID: 19460479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathophysiology of Calcium, Phosphorus, and Magnesium Dysregulation in Chronic Kidney Disease.
    Felsenfeld AJ; Levine BS; Rodriguez M
    Semin Dial; 2015; 28(6):564-77. PubMed ID: 26303319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and potential therapeutic strategies for the management of vascular calcification in patients with chronic kidney disease including those on dialysis.
    Ruderman I; Holt SG; Hewitson TD; Smith ER; Toussaint ND
    Semin Dial; 2018 Sep; 31(5):487-499. PubMed ID: 29733462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitamin K intake and mortality in people with chronic kidney disease from NHANES III.
    Cheung CL; Sahni S; Cheung BM; Sing CW; Wong IC
    Clin Nutr; 2015 Apr; 34(2):235-40. PubMed ID: 24745600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification.
    Salem S; Bruck H; Bahlmann FH; Peter M; Passlick-Deetjen J; Kretschmer A; Steppan S; Volsek M; Kribben A; Nierhaus M; Jankowski V; Zidek W; Jankowski J
    Am J Nephrol; 2012; 35(1):31-9. PubMed ID: 22179063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Serum Magnesium Levels on Kidney and Cardiovascular Prognosis and Mortality in CKD Patients.
    Galán Carrillo I; Vega A; Goicoechea M; Shabaka A; Gatius S; Abad S; López-Gómez JM
    J Ren Nutr; 2021 Sep; 31(5):494-502. PubMed ID: 33309408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized control trial to assess the impact of vitamin D supplementation compared to placebo on vascular stiffness in chronic kidney disease patients.
    Levin A; Perry T; De Zoysa P; Sigrist MK; Humphries K; Tang M; Djurdjev O
    BMC Cardiovasc Disord; 2014 Nov; 14():156. PubMed ID: 25381032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ambulatory arterial stiffness in chronic kidney disease: a methodological review.
    László A; Reusz G; Nemcsik J
    Hypertens Res; 2016 Apr; 39(4):192-8. PubMed ID: 26631849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Women and CKD-mineral and bone disorder.
    Ho LT; Sprague SM
    Adv Chronic Kidney Dis; 2013 Sep; 20(5):423-6. PubMed ID: 23978548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Moderate Aerobic Exercise Training on Endothelial Function and Arterial Stiffness in CKD Stages 3-4: A Randomized Controlled Trial.
    Van Craenenbroeck AH; Van Craenenbroeck EM; Van Ackeren K; Vrints CJ; Conraads VM; Verpooten GA; Kouidi E; Couttenye MM
    Am J Kidney Dis; 2015 Aug; 66(2):285-96. PubMed ID: 25960303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder.
    Diniz H; Frazão JM
    Nefrologia; 2013 Nov; 33(6):835-44. PubMed ID: 24158124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular remodeling and media calcification increases arterial stiffness in chronic kidney disease.
    Gauthier-Bastien A; Ung RV; Larivière R; Mac-Way F; Lebel M; Agharazii M
    Clin Exp Hypertens; 2014; 36(3):173-80. PubMed ID: 23786435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
    Toussaint ND; Pedagogos E; Tan SJ; Badve SV; Hawley CM; Perkovic V; Elder GJ
    Nephrology (Carlton); 2012 Jul; 17(5):433-44. PubMed ID: 22574672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease.
    Hutcheson JD; Goettsch C
    Circ Res; 2023 Apr; 132(8):993-1012. PubMed ID: 37053279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The emerging role of magnesium in CKD.
    Sakaguchi Y
    Clin Exp Nephrol; 2022 May; 26(5):379-384. PubMed ID: 35076791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Arterial stiffness and pulse pressure in CKD and ESRD.
    Briet M; Boutouyrie P; Laurent S; London GM
    Kidney Int; 2012 Aug; 82(4):388-400. PubMed ID: 22534962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.